Keryx to present phase-3 clinical data for Zerenex at conference

NEW YORK — Late-stage clinical trial data for a Keryx Biopharmaceuticals drug to treat kidney disease will be presented at a medical conference in Las Vegas.

Keryx said Monday that phase-3 data for the drug Zerenex (ferric citrate), a drug for abnormally high phosphate levels in patients with end-stage kidney disease on dialysis, will be presented at the upcoming National Kidney Foundation spring clinical meetings in April.

The company announced “positive” results from a phase-3 trial of the drug in November.

Login or Register to post a comment.